PapersPMID:20014183
A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL).
What moved
1 findingHow to read these marks →“At day 56, the MT group had lower AST than the placebo group (p= 0.04).”
- Study
- RCT
- Duration
- 4 weeks
- Dose studied
- silibinin target 5.1 mg/kg/day by weight band (80, 160, 240 or 320 mg/day), by mouth daily for 28 days
- Population
- children aged 1-21 with acute lymphoblastic leukaemia in maintenance chemotherapy with grade 2 or higher hepatic toxicity; AST at day 56, four weeks after the 28-day course ended
Study record
- Design
- randomised controlled trial
- Species
- human / mixed
- Population
- children with acute lymphoblastic leukemia in maintenance therapy with grade 2 or greater hepatic toxicity; plus CCRF-CEM T-cell ALL cells in vitro
- Participants
- 50
- Comparator
- placebo
- Duration
- 28 days
- Endpoints measured
- 30